Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Opicapone API Sources
NCT03820037Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by BIAL. Primary endpoints: Area under the plasma concentration-time curve from time zero to infinity at Day 14, Area under the plasma concentration-time curve from time zero to the last observable concentration at Day 14 and 1 more. Started Mar 2019; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03820037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820037.